

PRESS RELEASE

Of interest to editors and journalists covering:
Biotech, Medical Research, Pharmaceuticals, New York News

Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector

LOS ANGELES, Calif. and NEW YORK, NY -- (SEND2PRESS NEWSWIRE) -- April 5, 2005 -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer. In 2003, Rexin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Rexin-G as an effective treatment for pancreatic cancer.

Six out of six initial patients with advanced pancreatic cancer responded favorably to Rexin-G, as evidenced by significant shrinkage and/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Rexin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.

Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Rexin-G, to seek and destroy metastatic tumors. Following the success of "compassionate use" clinical trials using Rexin-G for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States.

In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that, "We are now in an excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."

About Epeius

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that was formed to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genetic medicine preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic side effects or organ damage.

More information: <http://www.epeiusbiotech.com>

#

NEWS SOURCE: Epeius Biotechnologies Corporation

WEBSITE: <http://www.epeiusbiotech.com>

MEDIA CONTACT(S):

Dr. Frederick L. Hall
President and CEO
of Epeius Biotechnologies Corporation
+1-818-771-7344
FAX: 818-243-7778

info @ epeiusbiotech.com

Note to editors: Important Note - to reach the person sending
the news release, contact: info @ epeiusbiotech.com

Information from Send2Press Newswire may be redistributed
in part or in whole by members of the media.
Copr. (C) Send2Press, a unit of Neotrope(R). All rights reserved.

TXT: <http://www.Send2Press.com/mediadrome/2005-04-0405-001.txt>

PDF: http://www.Send2Press.com/mediadrome/news_2005-04-0405-001.pdf

RSS: <http://www.Send2Press.com/XML/s2p-news.xml>

This release was issued on behalf of the above organization, who is solely
responsible for accuracy of content, by Send2Press(R) Newswire, a unit of
Neotrope(R).
<http://www.Send2Press.com>

[related: <http://www.CaliforniaNewswire.com>]